Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
TISSUE POLYPEPTIDE SPECIFIC ANTIGEN AND CANCER-ASSOCIATED SERUM ANTIGEN IN THE FOLLOW-UP OF OVARIAN-CANCER
Autore:
SLIUTZ G; TEMPFER C; KAINZ C; MUSTAFA G; GITSCH G; KOELBL H; BIEGELMAYER C;
Indirizzi:
UNIV VIENNA,DEPT GYNECOL & OBSTET,SPITALGASSE 23 A-1090 VIENNA AUSTRIA UNIV VIENNA,GEN HOSP,DEPT GYNECOL & OBSTET A-1090 VIENNA AUSTRIA UNIV VIENNA,GEN HOSP,DEPT LAB DIAGNOST,DIV ENDOCRINOL A-1090 VIENNA AUSTRIA
Titolo Testata:
Anticancer research
fascicolo: 3, volume: 15, anno: 1995,
pagine: 1127 - 1129
SICI:
0250-7005(1995)15:3<1127:TPSAAC>2.0.ZU;2-Q
Fonte:
ISI
Lingua:
ENG
Soggetto:
TUMOR-MARKER; CA-125; CARCINOMA; ASSAY; CASA;
Keywords:
TISSUE POLYPEPTIDE SPECIFIC ANTIGEN; CANCER ASSOCIATED SERUM ANTIGEN; OVARIAN CANCER;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
20
Recensione:
Indirizzi per estratti:
Citazione:
G. Sliutz et al., "TISSUE POLYPEPTIDE SPECIFIC ANTIGEN AND CANCER-ASSOCIATED SERUM ANTIGEN IN THE FOLLOW-UP OF OVARIAN-CANCER", Anticancer research, 15(3), 1995, pp. 1127-1129

Abstract

420 clinical and serological examinations prior to surgery and duringfollow-up were performed in 30 patients suffering from ovarian cancer. The population consisted of three FIGO stage Ia, nine stage Ic, fourstage II and fourteen stage III cases. Serous carcinoma of the ovary,mucinous carcinoma and other kinds of oval inn cancer were found in 16, 9 and 5 cases, respectively. The serum levels of the tumor markers tissue polypeptide specific antigen (TPS), cancer associated serum antigen (CASA) and carbohydrate antigen 125 (CA 125) were determined. Cut-off values of 97 U/l, 4 U/ml and 35m U/ml for TPS, CASA and CA 125, respectively, were selected according to the 95% of serum concentrations measured in healthy controls. Sen sitivity, specificity, PPV and NPVof CA 125 were 75%/96%/69%/92%, respectively. Sensitivity,, specificity, PPV and NPV of TPS were 67%/54%/59%/90%, respectively. CASA showeda sensitivity of 58%, specificity of 96% and a PPV and NPV of 73%/94%, respectively. The combination of TPS and CA125 increased the sensitivity to 81%, reaching a specificity of 82% and a PPV and NPV of 58/96%, respectively. The combination of CASA and CA125 showed a sensitivity, specificity, PPV and NPV of 55/85/65/96%, respectively. Twelve patients developed recurrence of disease after response to primary treatment. TPS, CASA and CA 125 detected recurrent disease in six, two and four cases, respectively. For TPS mean lead time was 4.6 months (range 2-18 months), for CASA 1.7 months (range 1-6 months), and for CA 125 3.5months (range 1-24 months. As a matter of fact TPS never showed lead time effects in patients without elevated pretherapeutic levels. A combination of all makers showed a mean lead time of 6.72 months. Detection of recurrent disease by CA 125 is improved when CA 125 is used in combination with TPS, especially in those patients with pretherapeutically elevated TPS serum levels.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/09/20 alle ore 13:59:26